Drugs / human pluripotent stem cell-derived cardiomyocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05223894 | Jun 2022 → Dec 2025 | heart failure | HELP Therapeutics Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human pluripotent stem cell-derived cardiomyocytes | “Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery.” NCT05223894 ↗ |
| Known as | hPSC-CMs | “Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery.” NCT05223894 ↗ |
| Modality | Cell therapy | “Patients with heart failure will be treated with allogenic human pluripotent stem cell-derived cardiomyocytes ( hPSC-CM ) from healthy donors.” NCT05223894 ↗ |
| Route | Other | “will be injected into the myocardium” NCT05223894 ↗ |